Clinical trials recruiting for Colorectal cancer
50
Recruiting trials
33
US states with sites
25
Countries
16%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Pembrolizumab | 3 |
| Cetuximab | 2 |
| Neoantigen-based peptide vaccine | 2 |
| RMC-6236 | 2 |
| daraxonrasib | 2 |
| 68Ga-DFC413 | 1 |
| 68Ga-NNS309 | 1 |
| ABT-301 | 1 |
| Adagrasib | 1 |
| BMS-986523 | 1 |
| Bevacizumab | 1 |
| Bevacizumab (Avastin) | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 12 |
| California | 9 |
| Virginia | 9 |
| Florida | 7 |
| Tennessee | 7 |
| Arizona | 6 |
| Maryland | 6 |
| Massachusetts | 6 |
| New York | 6 |
| Minnesota | 5 |
| Ohio | 5 |
| Connecticut | 4 |
Top cities
Houston, Texas 7Boston, Massachusetts 6Fairfax, Virginia 6Nashville, Tennessee 6San Antonio, Texas 6Baltimore, Maryland 5Dallas, Texas 5New York, New York 5Jacksonville, Florida 4Los Angeles, California 4
Self-screener
Recruiting trials
- A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
- A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
- A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer
- A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
- A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
- A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
- A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
- Advanced Therapies for Liver Metastases
- Advances in Imaging to Assess Response in Rectal Cancer
- Artificial Intelligence-assisted Colonoscopy in the Detection and Characterization of Colorectal Lesions
- CARE-CRC: Microbiome Insights and Correlations for Risk and Outcomes in Colorectal Cancer
- Collection of Samples USOPTIVAL Study
- Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)
- Effects of Endocrine Disruptors on the Gut Microbiota and Assessment of Their Impact on Colorectal Cancer Development (PERMICA)
- Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
- Evaluation of Gixam's Performance in a FIT Negative Population
- Examination of the Large Intestine With Camera Capsule in Patients With Blood Stream Infection With Gut-associated Bacteria
- Faecal Immunochemical Tests (FIT) for Surveillance After Colorectal Cancer (CRC) Study
- Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients
- Improving Colorectal Cancer Early Screening in Portugal: Identification of Gut Microbiome Biomarkers in Stool (GUTBIOME-PT)
- KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study
- Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
- Neoantigen-based Peptide Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment
- Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment
- Neoantigen-loaded DC Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment
- Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
- Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
- Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer
- Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
- Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer
- Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study
- Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
- Smart Pill for Measuring Gut Health in Colon Inflammation and Colon Cancer
- Spanish Registry of Digestive Tumours RETUD
- Spatial RadiomIcs and TRanscriptomics to the DIscovery of the Cross-link Between Colon Cancer and ChrOnic Kidney Disease
- Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
- Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer
- TIVA Versus Balanced Anesthesia on Muscle Mass in CRC Surgery
- TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
- Transcutaneous Electrical Acustimulation on Postoperative Bowel Function Recovery in Elderly Patients
- Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer
- mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC
Related conditions
Trials recruiting for Colorectal cancer often also study these conditions. Each links to its own recruiting-trial list.
Colorectal cancer 1359Lung cancer 2180Pancreatic cancer 870Non-small cell lung cancer 507Pancreatic Ductal Adenocarcinoma (PDAC) 32Breast cancer 2239Advanced Solid Tumors 35Renal Cell Carcinoma (RCC) 10Prostate cancer 1234Melanoma 487
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Colorectal cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.